CAN-1012 SR is under clinical development by CanWell Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAN-1012 SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAN-1012 SR overview
CAN-1012 is under development for the treatment of advanced metastatic solid tumors, melanoma, merkel cell carcinoma, metastatic breast cancer, metastatic renal cell carcinoma, head and neck cancer squamous cell carcinoma, sarcomas, transitional cell cancer (urothelial cell cancer), vulvar cancer, vaginal cancer, penile cancer, cervical cancer and metastatic colorectal cancer. It is administered through intratumor route as injection. The therapeutic candidate is sustained release formulation and acts by targeting TLR7.
For a complete picture of CAN-1012 SR’s drug-specific PTSR and LoA scores, buy the report here.